4basebio PLC (AIM: 4BB), the Cambridge-based synthetic DNA manufacturer focused on next-generation genomic medicines and advanced therapies, has announced a live investor presentation scheduled for 12 November 2026 at 17:00 GMT on the Investor Meet Company platform. The session will be led by Chief Executive Officer Dr. Amy Walker and Chief Financial Officer Richard Bungay, and is open to both existing and potential shareholders. The event provides investors with a direct opportunity to engage with the company's senior leadership team ahead of questions submitted via the platform.

Key Points

  • 4basebio PLC (AIM: 4BB) is a Cambridge-based biotechnology company specialising in synthetic DNA manufacturing for genomic medicines and advanced therapies.
  • The company will host a live investor presentation on 12 November 2026 at 17:00 GMT via the Investor Meet Company platform.
  • Questions may be submitted in advance through the Investor Meet Company dashboard until 09:00 GMT on 11 November 2026, or during the live session itself.
  • Investors should watch for any operational or strategic updates delivered during the presentation by CEO Dr. Amy Walker and CFO Richard Bungay.

Dr. Amy Walker and Richard Bungay to Present 4basebio's Strategy to Shareholders on 12 November

The presentation will be delivered by Dr. Amy Walker, Chief Executive Officer, and Richard Bungay, Chief Financial Officer, on the Investor Meet Company platform. The session is open to all existing and potential shareholders, reflecting the company's commitment to broad investor access. Those who already follow 4basebio PLC on the platform will be automatically invited, while new participants can register for free using the dedicated link provided in the company's announcement. Questions may be submitted in advance via the dashboard until 09:00 GMT on 11 November 2026, or posed during the live event itself.

4basebio's Enzymatic DNA Synthesis Platform Targets Gene Therapy and mRNA Production Markets

4basebio operates through a proprietary enzymatic DNA synthesis platform that produces GMP-grade synthetic DNA and mRNA. The company states that its technology offers superior speed, purity, and scalability compared with traditional plasmid-based systems. Its product range includes application-specific DNA constructs tailored to gene therapies, genome editing, mRNA production, and DNA vaccines. The company's model is focused on helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently, positioning 4basebio within the rapidly evolving advanced therapeutics and genomic medicine supply chain.

Cairn Financial Advisers, RBC Capital Markets, and Cavendish Capital Markets Support 4basebio's AIM Listing

4basebio's adviser and broker structure includes Cairn Financial Advisers LLP as Nominated Adviser, with RBC Capital Markets and Cavendish Capital Markets Limited serving as Joint Corporate Brokers. ICR Healthcare acts as media and investor relations adviser. This established capital markets infrastructure supports the company's AIM-listed status and ongoing engagement with the investment community. Investors following sector developments in synthetic biology, gene therapy supply chains, and mRNA technology platforms may find the upcoming presentation relevant to assessing the company's near-term operational direction.